Literature DB >> 12201495

Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma.

Jacqueline Vuky1, Richard Yu, Lawrence Schwartz, Robert J Motzer.   

Abstract

Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12201495     DOI： 10.1023/a:1016270206374

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  11 in total

Review 1.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

2.  Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide.

Authors:  T C Zhang; E H Cao; J F Li; W Ma; J F Qin
Journal:  Eur J Cancer       Date:  1999-08       Impact factor: 9.162

3.  Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.

Authors:  C Niu; H Yan; T Yu; H P Sun; J X Liu; X S Li; W Wu; F Q Zhang; Y Chen; L Zhou; J M Li; X Y Zeng; R R Yang; M M Yuan; M Y Ren; F Y Gu; Q Cao; B W Gu; X Y Su; G Q Chen; S M Xiong; T D Zhang; S Waxman; Z Y Wang; Z Chen; J Hu; Z X Shen; S J Chen
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

4.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

5.  Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.

Authors:  X H Zhu; Y L Shen; Y K Jing; X Cai; P M Jia; Y Huang; W Tang; G Y Shi; Y P Sun; J Dai; Z Y Wang; S J Chen; T D Zhang; S Waxman; Z Chen; G Q Chen
Journal:  J Natl Cancer Inst       Date:  1999-05-05       Impact factor: 13.506

6.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.

Authors:  G Q Chen; J Zhu; X G Shi; J H Ni; H J Zhong; G Y Si; X L Jin; W Tang; X S Li; S M Xong; Z X Shen; G L Sun; J Ma; P Zhang; T D Zhang; C Gazin; T Naoe; S J Chen; Z Y Wang; Z Chen
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

7.  Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis.

Authors:  G J Roboz; S Dias; G Lam; W J Lane; S L Soignet; R P Warrell; S Rafii
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

8.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.

Authors:  G Q Chen; X G Shi; W Tang; S M Xiong; J Zhu; X Cai; Z G Han; J H Ni; G Y Shi; P M Jia; M M Liu; K L He; C Niu; J Ma; P Zhang; T D Zhang; P Paul; T Naoe; K Kitamura; W Miller; S Waxman; Z Y Wang; H de The; S J Chen; Z Chen
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

9.  Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.

Authors:  Z G Wang; R Rivi; L Delva; A König; D A Scheinberg; C Gambacorti-Passerini; J L Gabrilove; R P Warrell; P P Pandolfi
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113

10.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860
View more
  16 in total

1.  Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.

Authors:  Pei-Chih Lee; Rajesh Kakadiya; Tsann-Long Su; Te-Chang Lee
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

2.  Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

Authors:  Malcolm A Smith; Min H Kang; C Patrick Reynolds; Raushan T Kurmasheva; Denise Alexander; Catherine A Billups; Jeffrey A Toretsky; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2012-02-07       Impact factor: 3.167

Review 3.  Arsenic trioxide - An old drug rediscovered.

Authors:  Ashkan Emadi; Steven D Gore
Journal:  Blood Rev       Date:  2010-05-15       Impact factor: 8.250

4.  Resveratrol protects against arsenic trioxide-induced oxidative damage through maintenance of glutathione homeostasis and inhibition of apoptotic progression.

Authors:  Chengzhi Chen; Xuejun Jiang; Yanhao Lai; Yuan Liu; Zunzhen Zhang
Journal:  Environ Mol Mutagen       Date:  2014-10-23       Impact factor: 3.216

5.  Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial.

Authors:  Bing Liu; Jian-wen Huang; Yong Li; Bao-shan Hu; Xu He; Wei Zhao; You-bing Zheng; Li-gong Lu
Journal:  J Cancer Res Clin Oncol       Date:  2014-12-14       Impact factor: 4.553

6.  Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin.

Authors:  Majid Momeny; Majid Zakidizaji; Reza Ghasemi; Ahmad R Dehpour; Maryam Rahimi-Balaei; Yassan Abdolazimi; Ardeshir Ghavamzadeh; Kamran Alimoghaddam; Seyed H Ghaffari
Journal:  Med Oncol       Date:  2009-09-10       Impact factor: 3.064

7.  Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment.

Authors:  Yangyang Xu; Xin Gu; Mancheng Gong; Guiying Guo; Kaiyu Han; Ruihua An
Journal:  Cancer Biol Ther       Date:  2013-08-05       Impact factor: 4.742

Review 8.  Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.

Authors:  Elden P Swindell; Patrick L Hankins; Haimei Chen; Denana U Miodragović; Thomas V O'Halloran
Journal:  Inorg Chem       Date:  2013-10-22       Impact factor: 5.165

Review 9.  In the war against solid tumors arsenic trioxide needs partners.

Authors:  Pochi R Subbarayan; Bach Ardalan
Journal:  J Gastrointest Cancer       Date:  2014-09

10.  Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.

Authors:  Chia-Chi Lin; Chiun Hsu; Chih-Hung Hsu; Wei-Ling Hsu; Ann-Lii Cheng; Chih-Hsin Yang
Journal:  Invest New Drugs       Date:  2006-08-26       Impact factor: 3.651
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.